FGF19 (Human) Recombinant Protein (P02)
- Known as:
- FGF19 (Human) Recombinant Protein (P02)
- Catalog number:
- H00009965-P02-25
- Product Quantity:
- 25 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- FGF19 (Human) Recombinant Protein (P02)
Related genes to: FGF19 (Human) Recombinant Protein (P02)
- Gene:
- FGF19 NIH gene
- Name:
- fibroblast growth factor 19
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-06
- Date modifiied:
- 2016-10-05
- Gene:
- HMCN2 NIH gene
- Name:
- hemicentin 2
- Previous symbol:
- -
- Synonyms:
- DKFZp434P0216, FLJ23816
- Chromosome:
- 9q34.11
- Locus Type:
- gene with protein product
- Date approved:
- 2005-06-03
- Date modifiied:
- 2018-11-16
- Gene:
- KCTD10 NIH gene
- Name:
- potassium channel tetramerization domain containing 10
- Previous symbol:
- -
- Synonyms:
- MSTP028, BTBD28
- Chromosome:
- 12q24.11
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-28
- Date modifiied:
- 2019-02-21
- Gene:
- RGPD4 NIH gene
- Name:
- RANBP2 like and GRIP domain containing 4
- Previous symbol:
- -
- Synonyms:
- RGP4, DKFZp686P0288
- Chromosome:
- 2q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-12-15
- Date modifiied:
- 2019-02-18
- Gene:
- WIPI2 NIH gene
- Name:
- WD repeat domain, phosphoinositide interacting 2
- Previous symbol:
- -
- Synonyms:
- ATG21, CGI-50, FLJ12979, FLJ14217, FLJ42984, DKFZP434J154, DKFZp686P02188, ATG18B
- Chromosome:
- 7p22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-11-15
- Date modifiied:
- 2016-03-01
Related products to: FGF19 (Human) Recombinant Protein (P02)
Related articles to: FGF19 (Human) Recombinant Protein (P02)
- /Aims Severe obesity is a major global health challenge and a key driver of hepatic steatosis through systemic insulin resistance and enhanced de novo lipogenesis. Excessive hepatic triglyceride accumulation represents a central metabolic consequence of this condition. This study aimed to identify immune-derived regulators of liver lipid metabolism and to define the mechanistic role of interleukin-13 (IL-13) in obesity-associated liver disease progression. - Source: PubMed
Publication date: 2026/09/03
von Bülow VerenaFelske Dejan ARiebeling Sarah BSchmidt Fabian PStettler FrederikSchmid AndreasKarrasch ThomasEder KlausMost ErikaMorlock GertrudHaase AnnikaBier JensHermanns Heike MGeier AndreasTuffs ChristopherPons-Kühnemann JörnRoderfeld MartinRoeb Elke - Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) arise from overlapping metabolic stress, gut-derived inflammatory input, immune activation, and fibrotic remodeling. Bile acids participate in cholesterol metabolism and lipid absorption, and they also regulate metabolic, intestinal barrier, immune, and inflammatory responses through farnesoid X receptor (FXR), G protein-coupled bile acid receptor 1 (TGR5/GPBAR1), fibroblast growth factor 19 (FGF19), and related signaling pathways. Accordingly, bile acids may constitute an important interface linking intrahepatic metabolic abnormalities with gut-liver inflammatory crosstalk, although many human findings remain associative and require cautious mechanistic interpretation. This review summarizes bile acid-axis dysregulation in MASLD/MASH, focusing on intrahepatic bile acid synthesis and transport, microbiota-mediated bile acid pool remodeling, intestinal barrier disruption, and the intrahepatic inflammatory-fibrotic niche. We propose that bile acid dysregulation should be interpreted beyond simple increases or decreases in total bile acid levels. Instead, it may reflect a systemic mismatch among bile acid pool composition, compartmental distribution, microbial transformation, and receptor-mediated signaling output. Future studies should integrate multi-compartment bile acid profiling with microbial enzyme activity, intestinal barrier assessment, and tissue-specific receptor signaling to support mechanism-based stratification, treatment-response monitoring, and rational combination strategies. - Source: PubMed
Publication date: 2026/08/18
Du YangQi LinShi YunzeHuang XingyuanShi XiaopeiLiu MingfengFang YingHu Xiaoyang - Diabetic kidney disease (DKD) is a major complication of type 2 diabetes (T2D). Fibroblast growth factor 19 (FGF19) is a key metabolic regulator, but its relationship with DKD, as defined by estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR), remains unclear. - Source: PubMed
Publication date: 2026/09/01
Jia YinanLiu SiyuXu TianliCao XiaojunShen LiminTang Mengjie - Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited genomic data in Asian populations. Lymph node metastasis heavily dictates prognosis, yet molecular determinants of progression remain poorly understood. We aimed to characterize the genomic landscape and explore candidate prognostic genomic features using paired primary and metastatic PSCC tumors. - Source: PubMed
Lou KexinLiang LinghuiCai HongzhouXu TingWang FufengWang DiJing QifanYin Jiani CZhang XiaoxiangXu Zicheng - Hepatic ischemia-reperfusion injury (HIRI) is a major cause of graft dysfunction and postoperative complications following liver transplantation and hepatic resection. Increasing evidence indicates that the gut-liver axis plays a central role in modulating hepatic injury, inflammation, and tissue regeneration during HIRI. - Source: PubMed
Publication date: 2026/08/26
de Oliveira Thiago Henrique CaldeiraGonçalves Gleisy Kelly Neves